Protocol Ledger

NCT03691779 · Phase III · COMPLETED

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Interventional Phase III clinical trial protocol NCT03691779 sponsored by Vertex Pharmaceuticals in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-10-02 Enrollment: 71 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03691779
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)71 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03691779
Protocol FieldVerified Registry Value
NCT IdentifierNCT03691779
Consolidated Lead SponsorVertex Pharmaceuticals
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment71 participants (ACTUAL)
Registered Start Date2018-10-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03691779
Hospital Research SiteLocationSite Profile
Children's Hospital of Orange CountyOrange, CAOpen Hospital Dossier ->
Children's Hospital ColoradoAurora, COOpen Hospital Dossier ->
Boston Children's HospitalBoston, MAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI